Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

References

• Hogan DB, Goldlist B, Naglie G, Patterson C. Comparison studies of cholinesterase inhibitors for Alzheimer’s disease. Lancet Neurol 2004;3:622–6
   PubMed Web of Science ®Google Scholar
• Moher D, Schulz KF, Altman DG; CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Clin Oral Investig 2003;7:2–7
   Google Scholar
• Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer’s Disease. CNS Drugs 1999;12:307–23
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington DC: American Psychiatric Association, 1994
   Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189–98
   Google Scholar
• McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–24
   PubMed Web of Science ®Google Scholar
• Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neurological test for severely demented patients. Arch Neurol 1994;51:41–5
   PubMed Web of Science ®Google Scholar
• Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136–9
   PubMed Web of Science ®Google Scholar
• Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):533–9
   Google Scholar
• Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14
   Google Scholar
• Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105–15
   PubMed Web of Science ®Google Scholar
• Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S51–6
   PubMedGoogle Scholar
• Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001;57:613–20
   PubMed Web of Science ®Google Scholar
• Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled, study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489–95
   PubMed Web of Science ®Google Scholar
• Klatte ET, Scharre DW, Nagaraja HN, Davis RA, Beversdorf DQ. Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17:113–6
   PubMed Web of Science ®Google Scholar
• Small G, Kaufer K, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005;59: 473–7
   Google Scholar
• Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819–26
   PubMed Web of Science ®Google Scholar
• Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002;127:6–19
   PubMedGoogle Scholar
• Potkin S. Butyrylcholinesterase: a target in the cholinergic treatment of Alzheimer’s disease. Prim Care Psych 2004;9:83–7
   Web of Science ®Google Scholar
• Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129–38
   Google Scholar
• Farlow MR, Lane R, Kudaravalli S, He Y. Differential qualitative responses to rivastigmine in APOE e4 carriers and noncarriers. Pharmacogen J 2004;4:332–5
   PubMed Web of Science ®Google Scholar
• Lane R, Farlow M. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer’s disease. J Lipid Res 2005;46:949–68
   PubMed Web of Science ®Google Scholar
• Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyryl cholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88–93
   PubMed Web of Science ®Google Scholar
• Darvesh S, Grantham DL, Hopkins DA. Distribution of butyryl cholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 1998;393:374–90
   Google Scholar
• Hartz-Schutt CG, Mai JK. Cholinesterase activity in the human striatum with special consideration of the terminal islands. J Hirnforsch 1991;32:317–42
   Google Scholar
• Wright CI, Geula C, Mesulam MM. Neuroglial cholinesterases in the normal brain and in Alzheimer’s disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993;34:373–84
   Google Scholar
• Royall DR. Executive cognitive impairment: a novel perspective on dementia. Neuroepidemiology 2000;19:293–9
   PubMed Web of Science ®Google Scholar
• Fogel BS, Brock D, Goldscheider F, Royall DR. Cognitive dysfunction and the need for long-term care: implications for public policy. Public Policy Issue Paper. Washington, DC: American Association of Retired Persons (AARP), 1994
   Google Scholar
• Holmes C, Ballard C, Lehmann D et al. Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005;76:640–3
   PubMed Web of Science ®Google Scholar
• Lane RM, Potkin SG, Enz A. Targeting acetyl- and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2005. In press
   Google Scholar
• O’Brien KK, Saxby BK, Ballard CG, et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 2003;13:231–9
   Google Scholar
• Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Annals Neurol 2003;54:235–8
   Google Scholar
• McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–6
   PubMed Web of Science ®Google Scholar
• Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001;13:199–205
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351:2509–18
   PubMed Web of Science ®Google Scholar
• Poewe W, Wolters W, Emre M, et al. Open-label extension study of rivastigmine in dementia associated with Parkinson’s disease. Mov Disord 2005. In press
   Google Scholar
• Moretti R, Torre P, Antonello RM, et al. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. Int J Clin Pract 2004;58:346–53
   PubMed Web of Science ®Google Scholar
• Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer’s disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159–69
   Google Scholar
• Erkinjuntti T, Skoog I, Lane R, Andrews C. Rivastigmine in patients with Alzheimer’s disease and concurrent hypertension. Int J Clin Pract 2002;56:791–6
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Skoog I, Lane R, Andrews C. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. Int J Clin Pract 2003;57:756–60
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Román G, Kalaria R, Lane R. Mechanisms of action and treatment benefits with cholinesterase inhibitors in patients with vascular cognitive disorders. J Drug Assess 2005;8:61–77
   Google Scholar
• Farlow M, Anand R, Messina Jr J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2000;44: 234–41
   Google Scholar
• Rogers SL, Doody RS, Pratt RD, Leni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10:195–203
   PubMed Web of Science ®Google Scholar
• Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD; Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58: 427–33
   Google Scholar
• Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R. Rivastigmine in Alzheimer’s disease: efficacy over two years. Am J Geriatr Psych 2004;12:420–31
   Google Scholar
• Bullock R, Passmore P, Wilkinson D et al. Participation in trials should be based on clinical uncertainty, not enforcement. BMJ 2000;320:511 (Letter)
   Google Scholar
• Schneider L. AD2000: donepezil in Alzheimer’s disease (Commentary). Lancet 2004;363:2100–1
   PubMed Web of Science ®Google Scholar
• Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract;2005;59:817–22
   PubMed Web of Science ®Google Scholar